210 related articles for article (PubMed ID: 27236105)
1. RASopathy Gene Mutations in Melanoma.
Halaban R; Krauthammer M
J Invest Dermatol; 2016 Sep; 136(9):1755-1759. PubMed ID: 27236105
[TBL] [Abstract][Full Text] [Related]
2. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Tajan M; Paccoud R; Branka S; Edouard T; Yart A
Endocr Rev; 2018 Oct; 39(5):676-700. PubMed ID: 29924299
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
4. Ras, Raf, and MAP kinase in melanoma.
Solus JF; Kraft S
Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
[TBL] [Abstract][Full Text] [Related]
5. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
Hernández-Martín A; Torrelo A
Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
[TBL] [Abstract][Full Text] [Related]
6. The NF1 gene in tumor syndromes and melanoma.
Kiuru M; Busam KJ
Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
[TBL] [Abstract][Full Text] [Related]
7. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
[TBL] [Abstract][Full Text] [Related]
8. Beyond the BRAF
Richtig G; Hoeller C; Kashofer K; Aigelsreiter A; Heinemann A; Kwong LN; Pichler M; Richtig E
Br J Dermatol; 2017 Oct; 177(4):936-944. PubMed ID: 28278349
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
[TBL] [Abstract][Full Text] [Related]
10. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
Bezniakow N; Gos M; Obersztyn E
Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
[TBL] [Abstract][Full Text] [Related]
11. The impact of RASopathy-associated mutations on CNS development in mice and humans.
Kang M; Lee YS
Mol Brain; 2019 Nov; 12(1):96. PubMed ID: 31752929
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations in signaling pathways in melanoma.
Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
[TBL] [Abstract][Full Text] [Related]
13. Toward a molecular classification of melanoma.
Fecher LA; Cummings SD; Keefe MJ; Alani RM
J Clin Oncol; 2007 Apr; 25(12):1606-20. PubMed ID: 17443002
[TBL] [Abstract][Full Text] [Related]
14. Malignancy in Noonan syndrome and related disorders.
Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
[TBL] [Abstract][Full Text] [Related]
15. RAS diseases in children.
Niemeyer CM
Haematologica; 2014 Nov; 99(11):1653-62. PubMed ID: 25420281
[TBL] [Abstract][Full Text] [Related]
16. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
Zenker M
Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
[TBL] [Abstract][Full Text] [Related]
17. The sixth international RASopathies symposium: Precision medicine-From promise to practice.
Gripp KW; Schill L; Schoyer L; Stronach B; Bennett AM; Blaser S; Brown A; Burdine R; Burkitt-Wright E; Castel P; Darilek S; Dias A; Dyer T; Ellis M; Erickson G; Gelb BD; Green T; Gross A; Ho A; Holder JL; Inoue SI; Jelin AC; Kennedy A; Klein R; Kontaridis MI; Magoulas P; McConnell DB; McCormick F; Neel BG; Prada CE; Rauen KA; Roberts A; Rodriguez-Viciana P; Rosen N; Rumbaugh G; Sablina A; Solman M; Tartaglia M; Thomas A; Timmer WC; Venkatachalam K; Walsh KS; Wolters PL; Yi JS; Zenker M; Ratner N
Am J Med Genet A; 2020 Mar; 182(3):597-606. PubMed ID: 31825160
[TBL] [Abstract][Full Text] [Related]
18. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
19. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Alsina J; Gorsk DH; Germino FJ; Shih W; Lu SE; Zhang ZG; Yang JM; Hait WN; Goydos JS
Clin Cancer Res; 2003 Dec; 9(17):6419-25. PubMed ID: 14695143
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.
Rauen KA; Huson SM; Burkitt-Wright E; Evans DG; Farschtschi S; Ferner RE; Gutmann DH; Hanemann CO; Kerr B; Legius E; Parada LF; Patton M; Peltonen J; Ratner N; Riccardi VM; van der Vaart T; Vikkula M; Viskochil DH; Zenker M; Upadhyaya M
Am J Med Genet A; 2015 Jan; 167A(1):1-10. PubMed ID: 25393061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
